News

The company has posted net loss of $670,000, compared to $979,000 for the same period last year. For the first quarter of 2011, Omnicell‘s loss from operations was

Concerta is a prescription product indicated as the treatment for attention deficit hyperactivity disorder (ADHD) for children ages 6 to 17 and in adults 18 to 65 as

The FilmArray RP, a multiplexed nucleic acid test for the simultaneous detection of 15 respiratory viruses, detects viral nucleic acids in nasopharyngeal swabs obtained from individuals suspected of

The patent entitled, ‘Transdermal Methods and Systems for the Delivery of Anti-Migraine Compounds,’ relates to methods of effectively treating a migraine using an iontophoretic patch containing a triptan.

CA4P is a type of drug called a vascular disrupting agent (VDA) as it selectively blocks blood vessels in tumors causing widespread tumor death. The study showed that

Jones has been working with Acura Pharma since April 2008 as the senior vice president and chief operating officer. Jones succeeds Andy Reddick, who passed away on 28

Keryx‘s operating loss was $6.48m, compared to $4.1m for the same period in 2010. Other research and development expenses, for the first quarter ended 31 March 2011, increased

As per the terms of the agreement, Prometheus is responsible to pay a sum of $19m upfront payment and development fees plus milestone payments and royalties on Rencarex

For the first quarter of 2011, the company has reported a net profit of EUR18.8m, or EUR0.81 per diluted share, compared to EUR3.2m, or EUR0.14 per diluted share,